
〈 Introduction 〉

“A new horizon of cancer immunotherapy”

Nagahiro Minato, MD., PhD.

Discovery of immune checkpoint mechanism in cancer and subsequent clinical success of the checkpoint blockade therapy have drastically changed the landscape of current cancer treatment in humans.

A main lesson from it is that endogenous immunity can have powerful potential and impact on cancer much more than previously thought, if it operates adequately.

The checkpoint blockade therapy is now followed by emerging, similarly promising immunotherapy with elegant genetic strategies, including gene-modified T cell therapy such as CAR-T.

In this symposium, current state of art on cancer immunity and immunotherapy is discussed.